Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil
Abstract Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high. Methods Among 937 patients with esophageal canc...
Main Authors: | Yu Ohkura, Masaki Ueno, Harushi Udagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-019-1665-x |
Similar Items
-
Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis
by: Giovanni Rosti, et al.
Published: (2011-09-01) -
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01) -
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
by: Reshma Mahtani, et al.
Published: (2021-05-01) -
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01) -
Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)